Whitehawk Therapeutics Inc. (NASDAQ:WHWK) dropped 8.81% in after-hours trading Thursday, closing at $2.38, after announcing a multi-year collaboration with Tempus AI.Check out the current price of WHWK stock here. WHWK closed Thursday at $2.61, up 23.70% on the day, according to Benzinga Pro data. Multi-Year Tempus AI CollaborationThe New Jersey-based oncology company announced a multi-year collaboration with Tempus AI Inc. (NASDAQ:TEM) aimed at advancing biomarker-driven research. The partnership will leve ...

Core Insights - AlphaTON Capital has been recognized by Nasdaq for its innovative approach to funding cancer research through asset tokenization, marking a significant milestone in the intersection of digital assets and medical research funding [3][9] - The partnership with Cyncado Therapeutics aims to revolutionize cancer treatment financing by creating a transparent and accessible investment mechanism that connects global investors with oncology research programs [4][5] Company Overview - AlphaTON Capital is a specialized digital asset treasury company focused on developing the TON and Telegram ecosystem, while also engaging in blockchain-based healthcare financing [3][11] - The company implements a comprehensive treasury strategy that includes direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders [11] Innovative Funding Model - The collaboration with Cyncado Therapeutics addresses critical challenges in cancer research funding, including enhanced liquidity, transparent allocation of funds, reduced barriers to entry for investors, and accelerated research timelines [7][8] - Tokenized assets provide greater flexibility and market access, allowing for a broader audience participation in medical innovation [7] Market Recognition and Future Plans - The recognition from Nasdaq signals growing institutional acceptance of tokenized assets in regulated markets, positioning AlphaTON Capital as a leader in the emerging institutional digital asset space [9] - The company plans to expand its tokenization initiative to additional therapeutic areas and research institutions, with several partnerships currently in development [10]

Core Insights - AlphaTON Capital Corp is at the forefront of the decentralized science (DeSci) movement, leveraging its TON infrastructure to enhance cancer research, particularly in mesothelioma through a non-binding letter of intent for tokenization of single-indication economics for TT-4 [1][2][4] Company Overview - AlphaTON is the only Nasdaq-listed company that operates a strategic TON token treasury while advancing first-in-class immunotherapy assets, integrating decentralized science principles with medical research funding [2][3] - The company aims to democratize access to cancer research and align global stakeholders with patient outcomes through innovative financing mechanisms [4][8] Clinical Development - Cyncado Therapeutics, a wholly owned subsidiary of AlphaTON, is preparing for the clinical start-up of TT-4, an oral A2B receptor antagonist, with first-patient dosing expected in Q1 2026 [5][14] - The initial study will focus on safety dose-escalation in solid tumor patients, followed by a larger mesothelioma-focused study at major U.S. cancer centers [5] Scientific Validation - Preclinical data for TT-4 shows promising results, including 90% tumor growth inhibition in murine models when combined with anti-PD-1 therapy and 60% complete responses [7][6] - The drug's mechanism aims to neutralize immune suppression and enhance anti-tumor responses, demonstrating superior activity compared to existing checkpoint inhibitors [7] Decentralized Science Movement - The DeSci movement seeks to transform how scientific research is funded and shared, with AlphaTON's tokenization initiative positioning it as a leader in this space [8][9] - The company aims to enhance transparency in clinical development and create direct value alignment between research supporters and therapeutic success [13] Strategic Vision - AlphaTON's business model integrates its validator operations, ecosystem investments, and therapeutic programs to create synergies that accelerate the path from laboratory to patient [9][10] - The exploratory LOI for tokenization is designed to preserve traditional therapeutic development pathways while exploring innovative funding models [10]

CERRITOS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), a pioneer in value-based community oncology care, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the Noble Capital Markets Emerging Growth Virtual Equity Conference, on October 8, 2025, including a presentation at 11:00am ET. Interested parties can access a webcast of the presentation by registering at the link listed on the Investor Relati ...

CERRITOS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), a pioneer in value-based community oncology care, is pleased to announce a new partnership with Protocol Behavioral Health, a leading provider of evidence-based mental health care for cancer patients. This collaboration underscores TOI’s commitment to delivering whole-person care by integrating behavioral health services directly into the cancer care journey. Research shows that approximately 30% of cancer patients ex ...

Lite Strategy Inc. (NASDAQ: LITS ) was formerly known as MEI Pharma, Inc. and traded under the ticker “MEIP.” LITS was an oncology firm working on two drug candidates, vorucliclib and ME-144, which could have been helpful as oncology comboMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Managem ...

Delcath Systems, Inc. (NASDAQ:DCTH) is a medical technology company focused on oncology. It develops and commercializes therapies for the treatment of primary and metastatic liver cancers. The company's main product is the Hepatic Delivery System, which administers high-dose chemotherapy to the liver while minimizing systemic exposure. Delcath operates in a competitive landscape with peers like Interpace Biosciences, EOM Pharmaceuticals Holdings, Aeterna Zentaris, and Rennova Health.In evaluating Delcath's ...

Company Overview - Guardant Health, Inc. is a leading precision oncology company focused on improving patient care and accelerating cancer therapies through advanced blood and tissue tests, real-world data, and AI analytics [3] - The company was founded in 2012 and aims to provide critical insights into cancer management, enhancing outcomes from screening to treatment selection [3] Recent Developments - Alex M. Azar II has been appointed to the board of directors of Guardant Health, bringing extensive experience from his role as the 24th Secretary of the U.S. Department of Health and Human Services [1][2] - Azar's background includes leadership positions in both government and the private sector, which will contribute to the company's strategic direction in cancer innovation and patient access [2] Product Innovations - Guardant Health has pioneered liquid biopsy technology and continues to innovate in this space, aiming to enhance cancer detection and management [2] - The company announced a positive clinical update for its Shield blood test, achieving a sensitivity of 84% and specificity of 90% for colorectal cancer detection [9] Strategic Partnerships - Guardant Health has formed a strategic agreement with LabFlorida/SunDx Labs to provide access to its Shield blood test in senior living communities, expanding its reach [6] - A partnership with PathGroup will bring the Shield blood test to over 250 hospitals and health systems across 25 states, significantly increasing its distribution [7]

Summary of Lyell Immunopharma FY Conference Call Company Overview - **Company**: Lyell Immunopharma (NasdaqGS:LYEL) - **Focus**: Clinical stage oncology company specializing in next-generation cell therapy for cancer, targeting both hematologic malignancies and solid tumors [3][4] Key Initiatives and Pipeline - **Lead Program**: RondaCell, a dual-targeting CD19/20 CAR T cell therapy for relapsed and refractory aggressive large B-cell lymphoma [3][4] - **Clinical Trials**: - Pivotal single-arm study for third-line treatment underway - Phase 3 randomized head-to-head trial launched for second-line treatment [3][4] Competitive Landscape - **RondaCell vs. Existing Therapies**: - RondaCell shows an 88% overall response rate and a 70% complete response rate in patients with relapsed disease, compared to 70% and 50% respectively for currently approved CD19 CARs [4][5] - Duration of complete response is emphasized as a critical metric for success [8][12] Data and Efficacy - **Response Rates**: - RondaCell's complete response rate at six months is 71%, significantly higher than Yescarta's 40% [8][12] - The company aims to demonstrate superior efficacy in harder-to-treat patient populations [10][12] Safety Profile - **Safety Data**: - RondaCell shows lower rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) compared to competitors [16] - 47% to 57% CRS rates for RondaCell versus 80% for Kite/Gilead products [16] Market Potential - **Market Disruption**: - The emergence of CD19/CD20 CAR therapies is expected to disrupt the existing CD19 CAR market, with potential for significant market share capture [17][18] - The company is confident in its product profile and aims to position RondaCell as a best-in-class therapy [18] Trial Design and Regulatory Path - **Pivotal Trials**: - Two pivotal trials are ongoing, with the third-line study being a single-arm study and the second-line study designed as a head-to-head trial against Yescarta and Breyanzi [19][22] - Primary endpoint for the second-line trial is event-free survival [23] Commercial Strategy - **Self-Sufficiency**: - The company believes it can independently commercialize RondaCell, with a manufacturing capacity of up to 1,200 doses per year [27][28] - Open to strategic partnerships but not urgent due to current capital and manufacturing capabilities [28] Future Outlook - **Data Readouts**: - Significant data updates expected by the end of the year for both third-line and second-line trials [30] - Continued data flow anticipated, with a focus on maturing trial results [30][31] Conclusion - Lyell Immunopharma is positioned to potentially redefine treatment paradigms in large B-cell lymphoma with RondaCell, leveraging strong clinical data, a favorable safety profile, and a strategic approach to market entry and commercialization [3][4][18]

Core Insights - Silexion Therapeutics Corp has selected AMS Advanced Medical Services GmbH as its contract research organization (CRO) to support upcoming Phase 2/3 clinical trials for SIL204, a next-generation siRNA candidate targeting KRAS-driven solid tumor cancers [1][2][3] - The partnership is expected to enhance Silexion's regulatory submissions to the Israel Ministry of Health in Q4 2025 and to the European Union in Q1 2026, with trials commencing in the first half of 2026 [2][3] - SIL204 has demonstrated up to 97% inhibition rates in preclinical studies across various cancer models, including pancreatic, colorectal, and lung cancers [3][5] Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference therapies for cancers driven by the mutated KRAS oncogene, which is prevalent in human cancers [6] - The company aims to advance its lead product candidate for locally advanced pancreatic cancer, building on positive trends observed in previous clinical trials [7] Clinical Development Strategy - The upcoming Phase 2/3 trial will evaluate SIL204's dual-route administration strategy, which combines intratumoral delivery to target primary tumors and systemic administration for metastatic disease [5] - Preclinical data supports the efficacy of SIL204 in significantly reducing both primary tumor growth and metastatic spread in relevant pancreatic cancer models [5] CRO Partnership - AMS brings over 28 years of experience in oncology clinical development and regulatory affairs, which is crucial for executing Silexion's clinical program effectively [2][4] - The collaboration will cover regulatory strategy, clinical trial design, site selection and management, and data analysis for the planned Phase 2/3 study [4]